Category: Investment

Founded in 2011, Meican is China’s largest group catering solutions provider. The Company offers comprehensive catering solutions to corporate clients and their employees, including both on-premise and off-premise catering and SaaS solutions. It also offers SaaS solutions to traditional group dining players, including digital ordering, integrated payment processing, catering operation, corporate fee control, as well as reporting & analytics.

Mitrassist is a leading angiocarpy treatment devices platform with globally cutting-edge innovation. It has introduced a minimally invasive approach to Mitral Regurgitation (MR) treatment that is neither repair nor replacement. The company’s “valve-in-valve” approach overcomes the various challenges of MR and offers an improved treatment solution for all MR patients.

NTX™ revolutionized the textile industry by introducing NTX™ Cooltrans™, a breakthrough waterless dyeing & printing system that delivers up to 90% in water savings, alongside dramatic reduction in energy usage and virtual elimination of water waste. With NTX™ Cooltrans™ as a foundation, the company has established a Southeast Asia-based ecosystem of textile processing plants to become the next generation sustainable eco- friendly supply chain partner for some of the world’s biggest fashion and apparel brands. NTX™ functions as a complete environmentally friendly textile processing solution provider by putting in place best practices, technical expertise, staff training, raw material sourcing and market opportunities across its ecosystem.

PhiSkin is a leading aesthetic medical clinic chain targeting mid-to-high-end customers in Beijing, Shanghai and other top tier cities in China. PhiSkin was founded in 2012 and is headquartered in Shanghai. As of today, PhiSkin has six clinics in operation across four cities – three in Shanghai, and one each in Beijing, Hangzhou, and Ningbo.

Instead of traditional plastic surgeries which typically require higher cost and a longer recovery period, Phiskin practices non- and minimal invasive treatments, notably thread lift, lower eyelid blepharoplasty and small-volume liposuction.

Qlife is a biomedical company developing high throughput mass spectrometry technology, which is fully Qlife is a biomedical company developing high throughput mass spectrometry technology, which is fully incorporated into omics study to drive for innovative medical laboratory tests and diagnosis. With headquarters in Shanghai and five regional laboratory service centers strategically located in China, Qlife offers innovative metabolomics/proteomics-based assays and laboratory diagnostic tests to enable early prevention and intervention of a variety of diseases. The R&D of Qlife is at the heart of the emerging fields of metabolomics and proteomics. Its proprietary platform and exclusive bioinformatics solutions are at the frontiers to deliver biomarker discoveries and innovative diagnostic tests, as well as aiming to make breakthroughs in precision medicine.

Seyond™, formerly Innovusion, is defined by devotion to its mission — to design, build, and mass produce the world’s highest-performing state-of-the-art LiDAR systems.

Headquartered in Silicon Valley, with additional facilities in Suzhou and Shanghai, Seyond represents the vanguard in long-range image-grade LiDAR and autonomous driving. Seyond’s technologies are enthusiastically embraced across automotive, smart transportation, rail transit, and industrial automation by industry leaders across the world.

Sinotau Pharmaceutical is an innovative pharmaceutical company focusing on the R&D, production and clinical application of a new generation of radiopharmaceuticals. Headquartered in Beijing, the company has set up radiopharmaceutical production bases in Jiangsu, Guangdong and Sichuan, and branches in the United States. Leveraging the world’s leading R&D resources in the field of radiopharmaceuticals and precision diagnosis and treatment, Sinotau has taken the lead in deploying a variety of targeted therapies and precision diagnostic radiopharmaceuticals in the fields of tumors, neurodegenerative diseases and cardiovascular diseases. The company’s pipeline has deployed multiple radiological diagnostic and therapeutic products, some of which have entered the stage of registered clinical research.

Taibang Biologic Group is a leading fully integrated plasma-based biopharmaceutical company in China. The company’s core capabilities include plasma collection, and the manufacturing and commercialization of human plasma-based biopharmaceutical products. These products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. As the company focuses on its plasma business, Taibang have expanded its product pipeline to include non-plasma biopharmaceutical products and bio-medical device products to complement its market position and expand its base of users in the growing core plasma therapeutic business.

UIB Healthcare Group is a leading pediatrics healthcare services provider with a primary focus in top-tier cities in China. The group currently owns and operates a number of hospitals and facilities in Beijing and Shanghai, including Beijing Jingdu Children’s Hospital, Shanghai Pubin Children’s Hospital and UIB International Maternity Care Center. With annual number of outpatient visits of 800,000 person-times, the group is one of the largest private hospital groups in China.

UIB Healthcare strives for the highest medical treatment standards and professional integrity, and takes pride in its highly-skilled medical team. Its facilities are leaders in treatment of specialties such as hematology, gastroenterology, cardiac surgery and children developmental behavior. For example, Beijing Jingdu Children’s Hospital has China’s largest hematology department and transplantation center.

Through continuous academic advancement across its core departments and improving its service quality, UIB Healthcare strives to become a first-class women’s and children’s healthcare brand in China, as well as a preferred platform for healthcare practitioners.